US2016113929A1PendingUtilityA1

Methods and compositions for treating viral or virally-induced conditions

64
Assignee: HEMAQUEST PHARMACEUTICALS INCPriority: Mar 11, 2010Filed: Jun 2, 2015Published: Apr 28, 2016
Est. expiryMar 11, 2030(~3.6 yrs left)· nominal 20-yr term from priority
Inventors:Ronald J. BerensonDouglas V. Faller
A61K 45/06A61K 31/27A61P 29/00A61K 38/15A61K 31/165A61K 31/167A61K 31/522A61K 31/4402A61K 31/473A61K 31/506A61P 31/22A61K 31/19A61K 31/4045A61K 31/513A61K 31/18A61K 38/12A61K 9/0053A61P 31/20A61P 31/12Y02A50/30A61K 31/52
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 .- 139 . (canceled) 
     
     
         140 . A method for treating and/or preventing a viral or virally-induced condition comprising administering a HDAC inhibitor and an antiviral agent wherein the viral or virally-induced condition is caused by a DNA virus and the HDAC inhibitor is administered at dose of less than 2 mg/kg per dose. 
     
     
         141 . The method of  claim 140 , wherein the HDAC inhibitor is CHR-3996. 
     
     
         142 . The method of  claim 140 , wherein the DNA virus is a herpesvirus. 
     
     
         143 . The method of  claim 140 , wherein the DNA virus is an Epstein-Barr virus. 
     
     
         144 . The method of  claim 140 , wherein the DNA virus is a cytomegalovirus. 
     
     
         145 . The method of  claim 140 , wherein the DNA virus is a varicella zoster virus. 
     
     
         146 . The method of  claim 140 , wherein the virally-induced condition is a lymphoma, chronic lymphocytic leukemia, nasopharyngeal carcinoma, gastric cancer, Kaposi's sarcoma, rheumatoid arthritis, systemic lupus erythematosus, or multiple sclerosis. 
     
     
         147 . The method of  claim 140 , wherein the antiviral agent is acyclovir (ACV), ganciclovir (GCV), valganciclovir, famciclovir, foscarnet, ribavirin, zalcitabine (ddC), zidovudine (AZT), stavudine (D4T), lamivudine (3TC), didanosine (ddI), cytarabine, dideoxyadenosine, edoxudine, floxuridine, idozuridine, inosine pranobex, 2′-deoxy-5-(methylamino)uridine, trifluridine and vidarabine. 
     
     
         148 . The method of  claim 140 , wherein the antiviral agent is ganciclovir (GCV). 
     
     
         149 . A method for treating and/or preventing a viral or virally-induced condition comprising administering a HDAC inhibitor and an antiviral agent wherein the viral or virally-induced condition is caused by a retrovirus and the HDAC inhibitor is administered at dose of less than 2 mg/kg per dose. 
     
     
         150 . The method of  claim 149 , wherein the HDAC inhibitor is CHR-3996. 
     
     
         151 . The method of  claim 149 , wherein the retrovirus is HIV, HTLV1 or HTLV2. 
     
     
         152 . The method of  claim 149 , wherein the retrovirus is HIV. 
     
     
         153 . A composition comprising a (i) HDAC inhibitor and (ii) an antiviral agent. 
     
     
         154 . The composition of  claim 153 , wherein the HDAC inhibitor is CHR-3996. 
     
     
         155 . The composition of  claim 153 , wherein the antiviral a herpesvirus antiviral. 
     
     
         156 . The composition of  claim 153 , wherein the antiviral agent is an anti-HIV antiviral. 
     
     
         157 . The composition of  claim 153 , wherein the antiviral agent is acyclovir (ACV), ganciclovir (GCV), valganciclovir, famciclovir, foscarnet, ribavirin, zalcitabine (ddC), zidovudine (AZT), stavudine (D4T), lamivudine (3TC), didanosine (ddI), cytarabine, dideoxyadenosine, edoxudine, floxuridine, idozuridine, inosine pranobex, 2′-deoxy-5-(methylamino)uridine, trifluridine and vidarabine. 
     
     
         158 . The composition of  claim 153 , wherein the antiviral agent is ganciclovir (GCV). 
     
     
         159 . The composition of  claim 153 , formulated for oral administration.

Join the waitlist — get patent alerts

Track US2016113929A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.